FI112946B - 4-hydroksi-1-okso-1,2-dihydro-pyridatsino-[4,5-b]-kinoliini-5-oksidijohdannaiset, niiden valmistus ja niiden käyttö glysiiniantagonisteina - Google Patents

4-hydroksi-1-okso-1,2-dihydro-pyridatsino-[4,5-b]-kinoliini-5-oksidijohdannaiset, niiden valmistus ja niiden käyttö glysiiniantagonisteina Download PDF

Info

Publication number
FI112946B
FI112946B FI990134A FI990134A FI112946B FI 112946 B FI112946 B FI 112946B FI 990134 A FI990134 A FI 990134A FI 990134 A FI990134 A FI 990134A FI 112946 B FI112946 B FI 112946B
Authority
FI
Finland
Prior art keywords
quinoline
oxo
hydroxy
dihydropyridazino
oxide
Prior art date
Application number
FI990134A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI990134A0 (fi
FI990134A (fi
Inventor
Ivars Kalvinsh
Wojciech Danysz
Markus Gold
Christopher Graham Rap Parsons
Irene Piskunova
Eugene Rozhkov
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of FI990134A0 publication Critical patent/FI990134A0/fi
Publication of FI990134A publication Critical patent/FI990134A/fi
Application granted granted Critical
Publication of FI112946B publication Critical patent/FI112946B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI990134A 1996-07-25 1999-01-25 4-hydroksi-1-okso-1,2-dihydro-pyridatsino-[4,5-b]-kinoliini-5-oksidijohdannaiset, niiden valmistus ja niiden käyttö glysiiniantagonisteina FI112946B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68634696 1996-07-25
US08/686,346 US5776935A (en) 1996-07-25 1996-07-25 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
EP9704057 1997-07-25
PCT/EP1997/004057 WO1998004556A1 (en) 1996-07-25 1997-07-25 Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists

Publications (3)

Publication Number Publication Date
FI990134A0 FI990134A0 (fi) 1999-01-25
FI990134A FI990134A (fi) 1999-03-24
FI112946B true FI112946B (fi) 2004-02-13

Family

ID=24755940

Family Applications (1)

Application Number Title Priority Date Filing Date
FI990134A FI112946B (fi) 1996-07-25 1999-01-25 4-hydroksi-1-okso-1,2-dihydro-pyridatsino-[4,5-b]-kinoliini-5-oksidijohdannaiset, niiden valmistus ja niiden käyttö glysiiniantagonisteina

Country Status (31)

Country Link
US (1) US5776935A (cs)
EP (1) EP0931081B1 (cs)
JP (1) JP3595342B2 (cs)
KR (1) KR100598206B1 (cs)
CN (1) CN1093860C (cs)
AR (1) AR004158A1 (cs)
AT (1) ATE224894T1 (cs)
AU (1) AU719993B2 (cs)
BR (1) BR9710569A (cs)
CA (1) CA2261923C (cs)
CZ (1) CZ289293B6 (cs)
DE (1) DE69715893T2 (cs)
DK (1) DK0931081T3 (cs)
EA (1) EA001711B1 (cs)
ES (1) ES2180041T3 (cs)
FI (1) FI112946B (cs)
GE (1) GEP20022801B (cs)
HK (1) HK1020193A1 (cs)
HU (1) HU223780B1 (cs)
IL (1) IL128225A (cs)
LT (1) LT4591B (cs)
LV (1) LV12260B (cs)
NO (1) NO310820B1 (cs)
PL (1) PL189572B1 (cs)
PT (1) PT931081E (cs)
SI (1) SI9720048B (cs)
SK (1) SK283536B6 (cs)
TW (1) TW402605B (cs)
UA (1) UA63911C2 (cs)
WO (1) WO1998004556A1 (cs)
ZA (1) ZA976612B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
EP1427404A4 (en) * 2001-08-20 2005-10-26 Maiken Nedergaard TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7029707B2 (en) * 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7294353B2 (en) * 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
CN1917892A (zh) * 2003-10-24 2007-02-21 草本制药科学有限责任公司 包含冬青的方法和组合物
SG161256A1 (en) * 2005-04-08 2010-05-27 Abbott Lab Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
BRPI0815957A2 (pt) * 2007-09-20 2019-09-24 Cortex Pharma Inc "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas"
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists
USD895157S1 (en) 2018-03-06 2020-09-01 IsoTruss Indsutries LLC Longitudinal beam
CN109912503B (zh) * 2019-04-01 2022-04-08 江南大学 一种2,3-二酰基喹啉类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore

Also Published As

Publication number Publication date
IL128225A0 (en) 1999-11-30
CN1093860C (zh) 2002-11-06
LT4591B (lt) 1999-12-27
AR004158A1 (es) 1998-11-04
ZA976612B (en) 1998-02-10
CN1228778A (zh) 1999-09-15
NO990306L (no) 1999-03-15
NO990306D0 (no) 1999-01-22
IL128225A (en) 2005-09-25
JP2000515872A (ja) 2000-11-28
HUP9903104A2 (hu) 2000-03-28
BR9710569A (pt) 1999-08-17
SI9720048B (sl) 2002-02-28
NO310820B1 (no) 2001-09-03
ES2180041T3 (es) 2003-02-01
EP0931081B1 (en) 2002-09-25
DE69715893T2 (de) 2003-01-30
HK1020193A1 (en) 2000-03-31
SI9720048A (sl) 1999-12-31
DE69715893D1 (de) 2002-10-31
AU719993B2 (en) 2000-05-18
FI990134A0 (fi) 1999-01-25
EA199900161A1 (ru) 1999-10-28
KR100598206B1 (ko) 2006-07-07
DK0931081T3 (da) 2003-01-27
CZ289293B6 (cs) 2001-12-12
CA2261923C (en) 2006-01-24
UA63911C2 (uk) 2004-02-16
CZ2019997A3 (cs) 1999-09-15
GEP20022801B (en) 2002-09-25
FI990134A (fi) 1999-03-24
EP0931081A1 (en) 1999-07-28
JP3595342B2 (ja) 2004-12-02
HUP9903104A3 (en) 2000-04-28
LV12260A (lv) 1999-04-20
AU4296997A (en) 1998-02-20
LV12260B (en) 1999-08-20
KR20000029568A (ko) 2000-05-25
SK283536B6 (sk) 2003-09-11
PL189572B1 (pl) 2005-08-31
LT99007A (en) 1999-07-26
PL331323A1 (en) 1999-07-05
CA2261923A1 (en) 1998-02-05
SK10399A3 (en) 2000-01-18
EA001711B1 (ru) 2001-06-25
ATE224894T1 (de) 2002-10-15
TW402605B (en) 2000-08-21
HU223780B1 (hu) 2005-01-28
PT931081E (pt) 2003-02-28
WO1998004556A1 (en) 1998-02-05
US5776935A (en) 1998-07-07

Similar Documents

Publication Publication Date Title
FI112946B (fi) 4-hydroksi-1-okso-1,2-dihydro-pyridatsino-[4,5-b]-kinoliini-5-oksidijohdannaiset, niiden valmistus ja niiden käyttö glysiiniantagonisteina
US8686002B2 (en) Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
TW200815432A (en) Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP3319762B2 (ja) 新規インドール―２，３―ジオン―３―オキシム誘導体
EP0581106B1 (en) Substituted aminothienopyridines, a process for their preparation and their use as medicaments
AU2023266373A1 (en) Kv7 channel activators compositions and methods of use
Zarghi et al. Synthesis and pharmacological evaluation of new 2-substituted-5-{2-[(2-halobenzyl) thio) phenyl}-1, 3, 4-oxadiazoles as anticonvulsant agents
HUT72501A (en) Derivatives of 5h,10h-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, preparation thereof and medicaments containing them
CA3178966A1 (en) N-(phenylaminocarbonyl) tetrahydro-isoquinolines and related compounds as modulators of gpr65
CN117088867A (zh) 可吸入型芳环并噻嗪及类似物、含其的药物组合物及其在抗炎、抗肿瘤中的应用
CN109890823A (zh) 稠合氮杂环化合物及其作为ampa受体调节剂的用途
AU741162B2 (en) New 2,3-benzodiazepine derivatives
Nishijima et al. Synthesis and diuretic activity of 2, 3-dihydro-4 (1H)-quinolinone 4-oxime-O-sulfonic acid derivatives
US20130116270A1 (en) Novel compounds
AU5749200A (en) Chromeno(4,3,2-de)isoquinolines as potent dopamine receptor ligands
WO2024056005A1 (zh) 多并环类化合物及其用途
Rashed Syntheses and structure-activity relationships of novel P2X3 receptor antagonists
JP2023531097A (ja) テトラヒドロイソキノリン類誘導体の塩、その製造方法及びその医薬学的応用
Barnard Synthesis and profiling of antimalarial side-chain modified pyrido [1, 2-a] benzimidazoles
Liszkiewicz et al. Synthesis and anxiolytic activity of 1-phenyl-2-(4-aryl-1, 3, 4, 5-tetrahydropyrido [2, 3-b][1, 4] diazepin-2-ylidene)-ethanone
CN110139855A (zh) 新型的氘代脲类化合物
KR19990071254A (ko) Nmda 수용체 길항제로 작용하는 4-(3-치환-2-옥소 및 2-티옥소-1,3-옥사졸리딘-5-일메톡시)-퀴놀린-2-카복실산 유도체